Theriva Biologics announced the first patient has been dosed in VIRAGE, the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.331 USD | -8.56% | -11.50% | -23.04% |
05-23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
05-07 | Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.04% | 6.25M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma